Hemostemix (CVE:HEM) Trading Up 31% – Still a Buy?

Hemostemix Inc. (CVE:HEM) shares traded up 31% on Friday . The stock traded as high as C$0.23 and last traded at C$0.19. 480,687 shares changed hands during trading, a decline of 9% from the average session volume of 525,664 shares. The stock had previously closed at C$0.15.

Hemostemix Price Performance

The firm has a 50-day simple moving average of C$0.20 and a two-hundred day simple moving average of C$0.12. The company has a market capitalization of C$27.69 million, a price-to-earnings ratio of -5.54 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.